Last reviewed · How we verify
rhuMAb Beta7 — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
rhuMAb Beta7 (rhuMAb Beta7) — Genentech, Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| rhuMAb Beta7 TARGET | rhuMAb Beta7 | Genentech, Inc. | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- rhuMAb Beta7 CI watch — RSS
- rhuMAb Beta7 CI watch — Atom
- rhuMAb Beta7 CI watch — JSON
- rhuMAb Beta7 alone — RSS
Cite this brief
Drug Landscape (2026). rhuMAb Beta7 — Competitive Intelligence Brief. https://druglandscape.com/ci/rhumab-beta7. Accessed 2026-05-14.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab